Papillomaviruses induce benign proliferative lesions, such as genital warts, in humans. The E2 gene product is thought to play a major role in the regulation of viral transcription and DNA replication and may represent a rational target for an antisense oligonucleotide drug action. Phosphorothioate oligonucleotides complementary to E2 mRNAs were synthesized and tested in a series of in vitro bovine papillomavirus (BPV) and human papillomavirus (HPV) models for the ability to inhibit E2 transactivation and virus-induced focus formation.
Papillomaviruses cause a spectrum of benign and malignant diseases in both animals (23) and humans (44) . Despite its widespread occurrence as a sexually transmitted disease (28) and its association with malignant disease (44) , no specific antiviral agents for papillomavirus exist. Current treatment of genital warts is nonspecific and consists primarily of surgical or chemical removal of the wart. These therapies are not curative because they are unable to produce a loss of the viral DNA episome that resides in the basal epithelium of latently infected patients.
Antisense oligonucleotides have been shown to be effective, specific inhibitors of gene expression (18) and to be active against a number viruses including Rous sarcoma virus (42) , vesicular stomatitis virus (1), herpes simplex virus type 1 (31) , influenza virus (43) , and human immunodeficiency virus (41) . Current information regarding gene structure and sequence and transcriptional regulation of a variety of papillomaviruses led us to adapt a number of papillomavirus gene expression and infection models in order to evaluate the potential use of antisense oligonucleotides as an approach to the treatment of human papillomavirus type 6 (HPV-6) and HPV-11-induced genital warts. We took advantage of the similarities in gene structure and function of bovine papillomavirus type 1 (BPV-1) and and HPV-11 to test the hypothesis that the E2 gene may represent a rational therapeutic target. The E2 open reading frame of papillomaviruses encodes a family of sequence-specific DNA-binding proteins that regulate transcription of papillomavirus early genes (26, 35 This observation was first made in BPV-1 (34) and has been extended to other papillomaviruses including HPV-11 (21) , , and HPV-18 (16) . In BPV-1, at least three E2 gene products have been identified: the full-length E2 gene which functions as a transcriptional transactivator, a truncated E2 gene which is transcribed from the promoter at nucleotide (nt) 3080 functions as a transcriptional transrepressor (22) , and a truncated E2 gene transcribed from the promoter at nt 890 that uses the splice donor/acceptor sites at nt 1235/3225 (6) .
The activities of BPV-1 promoters are strongly dependent upon an E2-dependent transcriptional enhancer located in the long control region of the BPV-1 genome. The promoters are responsible for the expression of the transforming gene E6, as well as genes E7 and El, which are involved in plasmid replication and which are regulated by the E2 responsive element E2RE1 located in the long control region (17, 33) . In addition, transcription from P2443, which directs transcription of the transforming gene E5 as well as that of gene E2, is under the control of E2RE1 (20) . Thus, E2 regulates the expression of viral genes responsible for transformation, replication, and transcriptional regulation.
In HPV the role of full-length E2 as a transcriptional transactivator versus its role as a transrepressor is less clear.
Full-length E2 has been shown to be a transcriptional transactivator that acts through E2 conditional enhancers (26) . Full-length E2 has also been demonstrated to act as a repressor of the E6 promoter for HPV-11 and for and HPV-18 (3, 5, 30 (8, 27) . On the basis of its critical position in the regulation of viral transcription and its direct role in viral DNA replication, E2 was selected as a target for antisense oligonucleotides. Oligonucleotides that are designed to bind to the E2 mRNA and, as a result, that inhibit the expression of E2 protein should disrupt the regulation of other papillomavirus gene products, should inhibit the life cycle of the virus, and may provide a novel class of selective antiviral compounds for the treatment of papillomavirus infection. HPV-6 and HPV-11 were selected because they are found in approximately 90% of genital condylomas (12, 13, 44) .
In this report we describe the in vitro activities of a series of oligonucleotides designed to hybridize to specific sequences within the BPV-1 E2 and HPV-11 E2 mRNAs. Phosphorothioate oligonucleotides were used in the studies in order minimize the potential metabolic inactivation of serum and cellular nucleases. As a result of the present investigation, antisense oligonucleotides which inhibit BPV-1 transactivation and transformation and HPV-11 E2 transactivation were identified.
MATERIALS AND METHODS
Cells and viruses. C127 mouse cells (10) were maintained in antibiotic-free Dulbecco modified Eagle medium, high glucose (4,500 mg/liter) supplemented with glutamine to 40 mM, and heat-inactivated (65°C, 30 min) fetal bovine serum to 10%. I-38 cells are a single cell clone derived from a single focus after infection of C127 cells with BPV-1.
BPV-1 was purified from experimentally induced fibropapillomas by double banding in cesium chloride as described previously (7) . Virions were characterized by electron microscopy (2) and enzyme-linked immunosorbent assay with a BPV-1 type-specific monoclonal antibody (7) . Viral DNA was characterized by digestion with a panel of restriction endonucleases, and biological activity was assessed by quantitative focus formation on C127 cells (10) .
Plasmids. Plasmid IPV100 contains the complete BPV-1 genome (7, 945 (39) . The compounds used in these experiments were shown to be greater than 90% pure with reference to contaminating oligonucleotides of different chain lengths by polyacrylamide gel electrophoreses and densitometric scanning.
Oligonucleotide modulation of E2-dependent transactivation. For BPV-1 E2 experiments, I-38 cells were plated 24 h prior to transfection at 5 x 104 cells per cm2 in 60-mm petri dishes. After attachment, cells were treated overnight with oligonucleotide by adding oligonucleotides to the medium at the stated concentrations. The next day, the medium was aspirated and replaced with fresh medium without oligonucleotide and was incubated for 1 h at 37°C in a humidified chamber. Cells were cotransfected with 10 ,ug each of IPV110 and PCH110 by the calcium phosphate coprecipitation method (15) . Four hours after transfection, cells were treated with 15% glycerol for 1 min (11), refed with medium containing oligonucleotide at the original concentration, and incubated for 48 h. After incubation, cells were washed with phosphate-buffered saline, scraped and transferred to a microcentrifuge tube, and centrifuged. Cells were suspended in 100 RI of 250 mM Tris-HCI and disrupted by three freeze-thaw cycles. Extracts were cleared by centrifugation, transferred to a fresh tube, and stored at -80°C until assayed for CAT and ,-galactosidase activities.
For inhibition of HPV-11 E2 transactivation, C127 cells were pretreated with oligonucleotide as described above; this was followed by cotransfection with 13 ,ug of IPV118 HPV-11 E2 expression plasmid, 5 ,ug of IPV120-15 E2-CAT reporter plasmid, and 2 ,ug of PCH110 as described above. Following transfection, cells were treated with oligonucleotide and were incubated for 48 h. Cells were harvested and processed for CAT and ,-galactosidase assays as described above.
CAT activity was determined by standard protocols (14) . Acetylated and nonacetylated reaction products were separated by thin-layer chromatography and were quantitated by using a Molecular Dynamics PhosphoImager (Molecular Dynamics, Sunnyvale, Calif.). 3-Galactosidase activity was determined by standard procedures (19) . To control for transfection efficiencies, data were normalized to P-galactosidase activity.
Inhibition (Fig. 1) . The shapes of the doseresponse curves for the two compounds differed. ISIS 1751 activity was concentration dependent to 500 nM, where it plateaued and exhibited no further activity to 5,000 nM. The activity of ISIS 1753 was dose dependent throughout the entire range tested and was able to reduce E2-dependent CAT activity to background levels.
ISIS 1755, which is complementary to the first initiation of translation codon distal to the promoter identified at nt 3080, increased E2-dependent transactivation in a concentrationdependent manner (Fig. 1) .
Inhibition of focus formation. Two compounds that inhibited E2 transactivation, ISIS 1751 and ISIS 1753, also inhibited BPV-1 focus formation on C127 cells (Fig. 2) . This effect was found to be concentration dependent with an IC50 of 10 nM for ISIS 1753. A clear IC50 for ISIS 1751 was not achieved, but it appeared to be in the range of 500 to 1,000 nM. ISIS 1755, which increased E2-dependent transactivation, had no effect on BPV-1 focus formation.
Optimization of chain length. To assess the effect of chain length on efficacy and potency, oligonucleotides of decreasing chain length, complementary to the initiation of the translation region of the E2 transactivator, were synthesized and tested in the E2 transactivation assay (Fig. 3) . Comparison of the IC5,s revealed that an oligonucleotide of 20 residues was the most potent inhibitor of E2 transactivation and that by the time oligonucleotides of 14 residues were used, all activity was lost. Increasing the chain length to 30 oligonucleotides did not result in increased activity (Fig. 1) . (Fig. 4) . Within a concentration range in which ISIS 2105 inhibited E2 transactivation up to 70%, ISIS 2324, a BPV-1 E2-specific oligonucleotide, did not produce a significant inhibitory effect in the HPV-11 E2 transactivation assay. This observation was expected since ISIS 2324 has minimal sequence homology with HPV-11. Similarly, ISIS 2105 had no effect on BPV-1 E2 transactivation, as measured in BPV-1-transformed cells (Fig. 1) .
ISIS 2105-induced, site-specific cleavage of HPV-1l E2 transcript by RNase H. RNase H is an endoribonuclease that specifically degrades the RNA strand of an RNA-DNA hybrid. This activity was used to test the ability of ISIS 2105 to hybridize to its target in a sequence-dependent manner.
The sequence to which ISIS 2105 hybridizes is approximately 117 bases from the 5' terminus of the T7-produced HPV-11 transcript. If ISIS 2105 hybridized to its target RNA in a sequence-specific manner, then RNase H should cleave off the 5'-terminal 117 bases. Both E. coli RNase H and HeLa cell nuclear extracts resulted in specific cleavage of the T7 transcript, consistent with the location of the ISIS 2105-binding site on the HPV-11 transcript (Fig. 5) HPV-11, the viral genome is maintained as a nuclear plasmid. This has not been achieved in cell culture for an HPV. BPV-1, however, is able to transform rodent cells and maintain its genome as a nuclear plasmid (10, 24) . Because of these properties, BPV-1 has been used as a model for latent infection and to study papillomavirus transcription and transformation. This model has been used to test the hypothesis that antisense oligonucleotides can provide papillomavirus-specific antiviral effects and that the BPV-1 model can be used to predict targets in analogous HPV RNA sequences that are sensitive to oligonucleotide-induced inhibition. Two such regions were identified: the mRNA cap region and the initiation of translation region, which are targeted by ISIS 1751 and ISIS 1753, respectively.
Inhibition of E2 transactivation by ISIS 1751 and ISIS 1753 was concentration dependent. ISIS 1751 is targeted to the 5' cap of the mRNA produced by the promoter at nt 2443 and is complementary to nts 2443 to 2472 (40) . Two additional mRNAs capable of producing full-length E2 transactivator have been identified in BPV-1-transformed cells (36, 38) . One is transcribed by the promoter located at nt 7940, and the other is transcribed by the promoter located at nt 890. Both of these mRNA species utilize the splice acceptor at nt 2558. Therefore, the sequences targeted by ISIS 1751 (nts 2443 to 2472) are not present in these mRNAs. This suggests that ISIS 1751 is capable of inhibiting only one species of E2 transactivator mRNA. BPV-1 can produce low levels of these alternate mRNAs, thus sustaining E2 expression in the absence of the mRNA produced from P2443. In dose-response experiments, ISIS 1753 was able to reduce E2-dependent CAT expression to background levels. This compound was targeted to the AUG of the full-length E2 transactivator mRNA located at nt 2608. ISIS 1753 was complementary to nts 2598 to 2627. This region is contained in all species of E2 transactivator mRNAs identified. This suggests that, unlike ISIS 1751, ISIS 1753 is capable of inhibiting E2 expression from all known E2 mRNAs, thus accounting for the differences in the dose-response curves in both the E2 transactivation assay and the focus formation assay.
The chain length of oligonucleotides is thought to affect not only the specificity of hybridization but also cellular uptake. Therefore, the effect of oligonucleotide chain length on activity was assessed by synthesis of a series of truncated oligonucleotides centered on the AUG of the E2 transactivator. In the present study, a minimum phosphorothioate oligonucleotide chain length of 20 residues was required to maintain maximum efficacy. Activity decreased significantly with each truncation until all activity was lost with a 14-mer. This apparent optimization of potency in a 20-nt oligonucleotide may be specific for this particular site in the RNA, the type of oligonucleotide, and/or the cell type in which it is evaluated. We are investigating the relationship between oligonucleotide length and activity in a number of antisense target models.
To test the effectiveness of BPV-1-specific oligonucleotides in the disruption of the virus life cycle, oligonucleotides that inhibited E2 transactivation were evaluated for their ability to inhibit BPV-1 focus formation. Both ISIS 1751 and ISIS 1753 were shown to inhibit focus formation in a concentration-dependent fashion. These results are consistent with reports that have shown that genetic mutation of E2 results in replication-and transformation-defective mutants (17) . Collectively, these findings provide further support that E2 is an essential gene in the life cycle of papillomaviruses and, as such, represents a rational target for papillomavirus therapy.
The nucleotide sequence of the RNAs that code for HPV-11 E2 protein differs significantly from those that code for the BPV E2 protein sequence. Therefore, oligonucleotides targeted to equivalent regions on the HPV and BPV RNAs have different nucleotide sequences. ISIS 2105, a sequence analog of the most potent and minimal-length phosphorothioate oligonucleotide targeted to the BPV-1 E2, was shown to produce dose-dependent inhibition of HPV-11 E2 transactivation. This compound had no inhibitory effect on BPV-1 transactivation. Conversely, ISIS 2324, the compound targeted to the BPV-1 E2 RNA, inhibited BPV-1 E2 transactivation with no effect on HPV-11 E2 activity. Taken together these data, which demonstrate that each phosphorothioate oligonucleotide was active in its homologous model and inactive in its heterologous model, provide evidence for (i) the requirement for oligonucleotide-RNA target complementarity and (ii) the sequence-specific inhibitory effect of ISIS 2105 on HPV-11 E2 expression.
The precise mechanism by which ISIS 2105, ISIS 2324, and the other active oligonucleotides modulate E2 transactivation has not been elucidated. At one level, the sequencespecific inhibitory effects described above are consistent with the initial design rationale of an antisense mechanism in which synthesis of E2 proteins is inhibited as a result of the oligonucleotide binding to their complementary receptorbinding site on the E2 mRNA.
At the level of the RNA target itself, a definitive mechanism of action for the oligonucleotides has not been assigned. One potential mechanism is hybridization arrest, in which protein synthesis is inhibited as a result of the binding of the oligonucleotide to the RNA, causing disruption of the protein translation process (25) . This mechanism is consistent with the finding that many potent oligonucleotides are targeted to sites associated with the initiation of translation.
Another possible molecular mechanism for these compounds is cleavage of the oligonucleotide-RNA complex by RNase H, leading to degradation of the RNA (18 Expression of BPV-1 (and HPV-6 and HPV-11) early genes is thought to be tightly regulated by the ratio of E2 transactivator:E2 transrepressor with expression of fulllength E2 transactivator subject to autoregulation (20, 26 
